The Administrative Core will oversee the scientific, fiscal, and organizational activities of the UPCI Lung Cancer SPORE, including oversight of scientific and translational progress, oversight of expenditures, scheduling regular meetings of the SPORE investigators, organizing our participation in annual SPORE meetings and interactions with the National Cancer Institute and other translational investigators, facilitating collaborations with other SPOREs and translational groups, and developing and preparing annual reports. The Administrative Core will also coordinate meetings with the Internal/External Advisory Board members, interact with our patient advocates, facilitate team science between investigators of different disciplines, undertake periodic evaluations of progress, and change direction of the SPORE Projects as necessary. The Administrative Core will use the SPORE flexibility provision to discontinue projects that fail to meet translational goals if needed. The Administrative Core will coordinate travel of SPORE investigators to the annual NCI-sponsored Translational Workshop, and other translational meetings, and will assist SPORE investigators in the preparation of manuscripts. The Core will oversee the Developmental Research and Career Development Programs to ensure smooth functioning of these components. The Administrative Core will coordinate SPORE Research Core activities with the UPCI to avoid redundancy and ensure that joint activities between the UPCI Lung and Thoracic Malignancies Program and the Lung Cancer SPORE are carried out efficiently, and that the two Programs act to complement and synergize with each other. The Administrative Core will also ensure that the SPORE Research Cores provide outstanding service to SPORE investigators. The Administrative Core will also communicate with the NCI Program Office to ensure that SPORE guidelines are followed and that the SPORE mandate is carried out. The Administrative Core will work with lung cancer Patient Advocates and lung cancer advocacy groups to raise lung cancer awareness and will work with the Development Office of UPC to secure philanthropy to supplement the SPORE budget.

Public Health Relevance

The Administrative Core will oversee all the activities of the SPORE and ensure that SPORE guidelines are followed, that investigators work toward the translation of their research to benefit lung cancer patients, that there is fiscal accountability and scientific integrity, and that the investigators work together as a team to maximize efficiency, avoid redundancy of effort, and increase productivity through collaboration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-12
Application #
8555308
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2001-06-01
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
12
Fiscal Year
2012
Total Cost
$180,603
Indirect Cost
$61,393
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Rothenberger, Natalie J; Somasundaram, Ashwin; Stabile, Laura P (2018) The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci 19:
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Isolation of Murine Alveolar Type II Epithelial Cells. Bio Protoc 7:
Dandachi, Nadine; Kelly, Neil J; Wood, John P et al. (2017) Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. Am J Respir Crit Care Med 196:353-363
Chatterjee, Suman; Huang, Eric H-B; Christie, Ian et al. (2017) Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC. Mol Cancer Ther 16:1658-1668
Yochum, Zachary A; Cades, Jessica; Mazzacurati, Lucia et al. (2017) A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Mol Cancer Res 15:1764-1776

Showing the most recent 10 out of 191 publications